Theranostics 2012; 2(5):427-436. doi:10.7150/thno.3794


How Does the Patient Benefit from Clinical PET?

Jens Sörensen

Section of Nuclear Medicine & PET, Department of Radiology, Oncology and Radiation Sciences. Uppsala University, SE-75185, Uppsala, Sweden.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
Sörensen J. How Does the Patient Benefit from Clinical PET?. Theranostics 2012; 2(5):427-436. doi:10.7150/thno.3794. Available from

File import instruction


Clinical molecular imaging by use of PET and PET/CT is increasingly important in routine oncological practice worldwide. A vast majority of clinical PET investigations are performed with [18F]-fluorodeoxyglucose (FDG), but there is a growing interest in novel molecular probes among scientists and clinicians. Beyond FDG, a small number of different tracers have been shown to be of clinical value. With a growing commercial interest in tracer development, many more are under investigation. This review provides some examples of clinical situations where tracers other than FDG have been found useful and an outlook towards technical and regulatory development needed to allow the full impact of clinical PET to benefit the individual patient.

Keywords: PET, PET/CT, [18F]-fluorodeoxyglucose, patient